News

Buy Metropolis Healthcare Ltd For Target Rs. 2,300 By Emkay Global Financial Services B2C and Wellness portfolios drive the beat MHL logged yet another strong quarter, with revenue growing 13% YoY, driven by B2C revenue improving 18% YoY. Test volume growth was robust across the B2B and B2C portfolios, growing 9% YoY. In line with our thesis (link), MHL’s aggressive network expansion plans (25 labs in FY25) and focus on the specialty and wellness portfolio will support volume trajectory in the medium term, in our view. With industry-wide pricing stabilizing and improv...
Buy Metropolis Healthcare Ltd For Target Rs. 2,300 By Emkay Global Financial Services
Buy Metropolis Healthcare Ltd For Target Rs. 2,300 By Emkay Global Financial Services
Source: Emkay Global Financial Services
2024-08-14 05:07:34 pm
Buy Metropolis Healthcare Ltd. For Target Rs.1,865 By JM Financial Services Ripe for a rally Core business revenue (ex-Covid, ex-PPP) grew 12% YoY (1% impact on account of floods) with 9% volume growth (key positive). B2C business continues to deliver strong mid-teens growth, particularly driven by core markets such as Mumbai (18%). Reported EBITDAM of 22.3% includes 0.8% impact of provision for Mohalla clinics business and 1.4% dilution on account of NACO contract expiry. Over the next 3 years, we expect a mid-teens revenue CAGR with meaningful margin expansion (...
Buy Metropolis Healthcare Ltd. For Target Rs.1,865 By JM Financial Services
Buy Metropolis Healthcare Ltd. For Target Rs.1,865 By JM Financial Services
Source: JM Financial Services
2024-04-21 02:21:16 pm
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests Dr. Lal PathLabs, India's biggest diagnostics firm by revenue, posted a higher profit for the third straight quarter on Thursday, due to more diagnostics and tests in the monsoon and winter seasons as well as an increase in COVID cases. The company's consolidated net profit jumped 54% year-over-year to 813 million rupees (nearly $10 million) in the third quarter. Its total revenue climbed by 10% to 5.39 billion rupees The October-December quarter encompasses the tail end of t...
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests
India`s Dr. Lal PathLabs posts 54% jump in Q3 profit on flu, COVID tests
Source: Reuters
2024-02-01 03:08:14 pm
Buy Metropolis Healthcare For Target Rs.1,430 - Yes Securities Moderate vols, mix dampen outlook Result Synopsis Metropolis reported another quarter of moderate volume growth of ~10% in core business (ex-Covid, PPP contract) on back of +9% volume in Q1. Margin was impacted by one-time receivables write-off (~1%) and the more recurring investment in lab network (added 7 labs in Q2). Company reiterated its lab and service centre expansion plans – additional 90 labs (to 270) and 1800 service centres (to 5,500) by 2025. We noted change in managem...
Buy Metropolis Healthcare For Target Rs.1,430 - Yes Securities
Buy Metropolis Healthcare For Target Rs.1,430 - Yes Securities
Source: Yes Securities Ltd
2023-12-12 04:11:56 pm
Buy Metropolis Healthcare Ltd For Target Rs1,635 -JM Financial Institutional Securities Ltd With price hikes early next year, PPP base reset in 4Q and ramp-up of newer labs, METROHL’s earnings momentum should accelerate, in our view. We expect mid-teens revenue CAGR with meaningful margin expansion (to 27%) to play out over the next 3 years. The recent 2Q performance was in line with JMFe. Core business revenue (ex-Covid, ex-PPP) grew 13.4% YoY. Reported EBITDA includes a one-time impact of INR 33mn pertaining to provision for adjustments related to employee fraud pursuant to ...
Buy Metropolis Healthcare Ltd For Target Rs1,635 -JM Financial Institutional Securities Ltd
Buy Metropolis Healthcare Ltd For Target Rs1,635 -JM Financial Institutional Securities Ltd
Source: JM Financial Institutional Securities Ltd
2023-11-24 01:12:40 pm